NASDAQ$HOLX
Hologic Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Hologic's Q4 2021 earnings exceeded expectations despite a decrease in COVID-19 assay sales.
Hologic announced strong Q4 2021 results, with revenue exceeding expectations. The company's diversified business, particularly in women's health, drove growth despite a decline in COVID-19 assay sales compared to the prior year period. Hologic is guiding for continued growth in fiscal year 2022, driven by core women’s health businesses and contributions from COVID-19 testing.
- Revenue reached $1.317 billion, a decrease of 2.3% year-over-year, driven by lower COVID-19 assay sales.
- Global revenue from Breast Health and GYN Surgical divisions grew 15.6% and 21.8%, respectively.
- Diagnostics revenue decreased by 10.9%, but excluding COVID-19 assays, grew by 5.1%.
- The company acquired Bolder Surgical for approximately $160 million.
Headline financials
Revenue & EPS history
Hologic · Revenue · Quarterly
$1.32B
Revenue by segment
Hologic · $1.88B total across 3 segments · Q4 2021
- Diagnostics$837M-10.9%44.6%
- Molecular Diagnostics$705M-14.0%37.6%
- Breast Health$334M+15.6%17.8%
Forward guidance
Hologic expects strong financial results in fiscal 2022, with solid growth in core women’s health businesses and a meaningful contribution from COVID-19 testing.
Tailwinds
- Expects strong financial results in fiscal 2022.
- Solid growth in core women’s health businesses.
- Meaningful contribution from COVID-19 testing.
- Acessa will be included in organic revenue for the full year.
- Biotheranostics and Diagenode will become part of organic revenue in the fiscal third quarter.
Headwinds
- Revenue $3,750 - $4,000 (33.4%) to (29.0%)
- GAAP EPS $2.50 - $2.80 (65.3%) to (61.2%)
- Non-GAAP EPS $3.55 - $3.85 (57.8%) to (54.2%)
- Q1 2022 Revenue $1,100 - $1,150 (31.7%) to (28.6%)
- Q1 2022 GAAP EPS $0.88 - $0.98 (64.8%) to (60.8%)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.5%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.1%
Avg return
30 days after
49%
35 / 72 earnings
Positive
+12.3%
Q3 2020
Best reaction
-11.4%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.0% | -0.6% | +0.7% | |
| Q4 2025 | +0.1% | +0.1% | +0.9% | |
| Q3 2025 | +2.8% | +4.4% | +3.3% | |
| Q2 2025 | -5.6% | -3.2% | +8.5% | |
| Q1 2025 | -10.1% | -11.4% | -11.3% | |
| Q4 2024 | -4.3% | -4.3% | -6.6% | |
| Q3 2024 | +4.9% | +6.4% | +2.2% | |
| Q2 2024 | +0.3% | -0.2% | -3.3% | |
| Q1 2024 | -2.7% | -0.4% | -1.1% | |
| Q4 2023 | +5.7% | +5.4% | +0.1% | |
| Q3 2023 | -5.1% | -5.9% | -5.4% | |
| Q2 2023 | -2.4% | -2.6% | -8.3% | |
| Q1 2023 | +3.8% | +3.6% | -1.1% | |
| Q4 2022 | +10.8% | +12.4% | +13.8% | |
| Q3 2022 | +1.0% | +1.3% | -3.4% | |
| Q2 2022 | +1.2% | +3.4% | +9.8% | |
| Q1 2022 | +4.0% | +3.8% | +2.4% | |
| Q4 2021 | -3.3% | -5.9% | -0.3% | |
| Q3 2021 | +2.3% | +5.0% | +9.7% | |
| Q2 2021 | -9.1% | -9.9% | -13.4% | |
| Q1 2021 | +1.7% | +11.2% | -3.3% | |
| Q4 2020 | +6.6% | -5.0% | +1.7% | |
| Q3 2020 | +12.3% | +14.8% | -2.8% | |
| Q2 2020 | +2.9% | +2.6% | +8.9% | |
| Q1 2020 | -0.7% | -1.8% | -13.7% | |
| Q4 2019 | -4.0% | +8.8% | +10.3% | |
| Q3 2019 | -1.3% | -6.5% | -4.1% | |
| Q2 2019 | -0.1% | +0.7% | -5.1% | |
| Q1 2019 | +0.6% | -0.5% | +8.6% | |
| Q4 2018 | +4.9% | +1.2% | +3.7% | |
| Q3 2018 | -3.5% | -1.9% | -7.5% | |
| Q2 2018 | -6.9% | -6.8% | -3.9% | |
| Q1 2018 | -6.7% | -6.6% | -2.2% | |
| Q4 2017 | +0.4% | +2.9% | +8.1% | |
| Q3 2017 | -9.3% | -11.3% | -12.5% | |
| Q2 2017 | -4.3% | -5.1% | -2.0% | |
| Q1 2017 | -2.6% | -2.9% | +1.8% | |
| Q4 2016 | +4.3% | +8.5% | +6.3% | |
| Q3 2016 | +3.9% | +5.8% | +5.3% | |
| Q2 2016 | -10.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +8.6% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | +5.1% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | +8.1% | — | — | |
| Q1 2014 | -5.9% | — | — | |
| Q4 2013 | -6.9% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -11.4% | — | — | |
| Q1 2012 | +5.2% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q3 2011 | -3.9% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q2 2009 | +2.9% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q4 2009 | +2.9% | — | — | |
| Q3 2009 | -3.0% | — | — | |
| Q3 2008 | -3.0% | — | — | |
| Q4 2008 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro